Chipmaker Qualcomm has struck a deal with Samsung that may quash its hefty antitrust case in South Korea and help ward off a hostile bid takeover from rival Broadcom. While the exact terms of the deal haven’t been disclosed, the new patent cross-licensing agreement stipulates that Samsung “will be withdrawing” its interventions in Qualcomm’s appeal against its US$854 million fine from the Korean Fair Trade Commission.
The two companies plan to work together on Qualcomm’s processors, facilitating a “transition to 5G.” Qualcomm has already agreed similar commitments from a number of Chinese smartphone makers, including Xiaomi, Oppo and Vivo.
The partnership will help to counteract the damaging effects of the numerous fines and legal battles the company has faced in recent times reported Nasdaq. The deal was announced as Qualcomm reported first-quarter revenue growth of just 1%, after it swung to a net loss of US$6 billion in the three months ending December 2017. It needs to start demonstrating strong growth again if it’s to avoid a hostile takeover bid from rival Broadcom which, if successful, would be the biggest takeover in tech history reported Nasdaq.
At time of writing, Qualcomm stock had risen 0.87% in after-hours trading.
Full Content: Nasdaq, Reuters & 9To5 Google
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas